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Abstract
Objective
To identify people with epilepsy who will not achieve a 12-month seizure remission within 5
years of starting treatment.
Methods
The Standard and New Antiepileptic Drug (SANAD) study is the largest prospective study in
patients with epilepsy to date. We applied a recently developed multivariable approach to the
SANAD dataset that takes into account not only baseline covariates describing a patient’s
history before diagnosis but also follow-up data as predictor variables.
Results
Changes in number of seizures and treatment history were the most informative time-
dependent predictors and were associated with history of neurologic insult, epilepsy type, age at
start of treatment, sex, and having a ﬁrst-degree relative with epilepsy. Our model classiﬁed 95%
of patients. Of those classiﬁed, 95% of patients observed not to achieve remission at 5 years
were correctly classiﬁed (95% conﬁdence interval [CI] 89.5%–100%), with 51% identiﬁed by 3
years and 90% within 4 years of follow-up. Ninety-seven percent (95% CI 93.3%–98.8%) of
patients observed to achieve a remission within 5 years were correctly classiﬁed. Of those
predicted not to achieve remission, 76% (95%CI 58.5%–88.2%) truly did not achieve remission
(positive predictive value). The predictive model achieved similar accuracy levels via external
validation in 2 independent United Kingdom–based datasets.
Conclusion
Our approach generates up-to-date predictions of the patient’s risk of not achieving seizure
remission whenever new clinical information becomes available that could inﬂuence patient
counseling and management decisions.
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Epilepsy is a heterogeneous disorder with respect to etiology,
seizures types, and outcome. Although for most patients
seizures can be controlled with antiepileptic drugs (AEDs),
≈30% never enter a sustained remission from seizures, despite
multiple treatment changes. Patients typically undergo years
of treatment before the clinician is conﬁdent that their epi-
lepsy is drug resistant.1,2 Uncontrolled seizures during this
time can have a pronounced reduction in quality of life, ed-
ucation, and employment prospects. The ability to reliably
predict earlier that seizure remission will not occur would
oﬀer the opportunity for more eﬀective management and
better patient counseling in an attempt to minimize adverse
eﬀects on quality of life.
The focus of this study is to predict patients who will not
achieve a 12-month remission by 5 years of follow-up using
covariates collected at baseline and during follow-up. Several
studies have assessed prognostic factors for outcomes in
newly diagnosed epilepsy,3–10 but prediction of drug-resistant
epilepsy based on baseline (or early follow-up) prognostic
factors has achieved areas under curves of only 61% to 78%.
This work is diﬀerent because we use data collected during
follow-up (referred to as longitudinal variables) in addition to
baseline covariates that describe a patient’s history before
diagnosis. Our approach generates up-to-date predictions
of the patient’s risk of not achieving seizure remission
whenever new clinical information becomes available, pro-
viding a framework to aid decision making.
Methods
Patients and procedures
The Standard and New Antiepileptic Drugs (SANAD)
trial11,12 is a randomized controlled trial that recruited 2,437
people with epilepsy assigned to 1 of 2 arms of the trial. Arm A
included those for whom carbamazepine was considered the
ﬁrst-line standard treatment, primarily patients with focal
epilepsy, who were randomized to treatment with carbama-
zepine, gabapentin, lamotrigine, oxcarbazepine, or top-
iramate. Arm B included those for whom sodium valproate
was considered the ﬁrst-line standard treatment, primarily
those with generalized or unclassiﬁed epilepsy, who were
randomized to lamotrigine, topiramate, or valproate. Clini-
cians recruiting patients into SANAD were primarily neurol-
ogists with expertise in epilepsy. This dataset contains a large,
heterogeneous group of patients with epilepsy, many of whom
have been observed for at least 5 years, and provides the
opportunity to investigate the individual proﬁles of patients to
predict those who will not achieve a 12-month continuous
seizure remission during follow-up. Our multivariate analysis
includes data from both arms of the SANAD study simulta-
neously. Previous analysis of the SANAD data used only
baseline covariates to identify prognostic factors inﬂuencing
a patient’s time to remission from seizures or treatment fail-
ure, and the development of a clinical classiﬁcation tool was
not addressed.13,14
This analysis considers 1,577 patients who achieved at least 1
continuous period of 12-month remission within 5 years from
starting treatment and 175 patients who did not. Patients were
included in our analysis if they had experienced at least 2
clinically deﬁnite unprovoked seizures, were at least 5 years
old, and had been followed up either to ﬁrst remission or for 5
years. Our aim was to correctly identify patients who did not
achieve remission as early as possible in their treatment
journey by looking at the individual proﬁles (using both
baseline and longitudinal data), and our primary outcome was
a binary variable indicating whether the patient achieves re-
mission within 5 years of starting treatment.
For the purposes of external validation, the Multicentre Study
of Early Epilepsy and Single Seizures (MESS)15 and National
General Practice Study of Epilepsy (NGPSE)16 datasets were
used, which come from aUnited Kingdom–based randomized
controlled trial and the UK primary care system, respectively.
Standard protocol approvals, registrations,
and patient consents
SANAD received appropriate multicenter and local ethics and
research committee approvals and was managed according to
the Medical Research Council’s Good Clinical Practice
Guidelines. Patients gave informed written consent to in-
clusion and to long-term follow-up. SANAD is registered as
an International Standard Randomised Controlled Trial (No.
ISRCTN38354748).17
Predictive models and follow-up data
Two models are ﬁtted, one for the remission group and one
for the no-remission group. These models are then used to
predict for a new patient the likelihood of not achieving re-
mission by assessing which of the 2 models the new patient’s
proﬁle is closer to. Predictions are updated each time new
information becomes available for a patient. The model does
not need to be reﬁtted, and the new patient’s data are used to
generate a patient-speciﬁc prediction of the risk of not
achieving remission.
In this study, 4 follow-up variables were considered for in-
clusion in the ﬁnal model based on clinical consensus. These
Glossary
AED = antiepileptic drug; AUC = area under the receiver operator characteristic curve; CI = conﬁdence interval; MESS =
Multicentre Study of Early Epilepsy and Single Seizures;NGPSE =National General Practice Study of Epilepsy; PPV = positive
predictive value; SANAD = Standard and New Antiepileptic Drug.
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were (1) whether a patient experienced seizures (of any type)
since their last clinic visit, (2) the total number of seizures
experienced since the last clinic visit, (3) whether treatment
was changed at the last visit, and (4) the number of adverse
events experienced by the patient since the last visit. Common
adverse events experienced included depression, dizziness,
allergic reactions, headaches, tiredness, pins and needles, and
weight gain.18 Treatment change could include the addition
or removal of an AED or a change in the dose of a drug.
The list of potential baseline covariates considered included
age at the start of treatment, sex, type of epilepsy, EEG results,
CT/MRI results, ﬁrst-degree relative with epilepsy, neuro-
logic insult, and total number of seizures experienced before
treatment was started. Patients were classiﬁed as having
a neurologic insult if they had learning disabilities or a neu-
rologic deﬁcit. Epilepsy type was classiﬁed as focal, general-
ized, or unclassiﬁed and is highly correlated with the
randomization arm to which the patient was recruited. EEG
and CT/MRI results were deﬁned as normal, not clinically
indicated, or abnormal. Previous analysis of the SANAD
dataset used these baseline covariates to identify prognostic
factors inﬂuencing a patient’s time to remission.13 In this
analysis, they are used to model the evolution over time of the
longitudinal variables that predict no-remission and only in-
directly inﬂuence the classiﬁcation procedure through their
inﬂuence on the longitudinal variables.
Models also accounted for time since starting treatment and
for time since the last follow-up to account for the fact that
clinic visits were not equally spaced.
Statistical methods
Multivariate generalized linear mixed modeling was applied to
model the longitudinal variables in each prognostic group
separately (patients who achieved 12-month remission and
patients who did not).19 Multivariate models account for the
correlation between repeated measurements over time and
for the dependence of the longitudinal variables on baseline
covariates.
Multivariate models were built by ﬁrst considering the subset
of baseline covariates that best described the changes over
time of each of the 4 longitudinal variables listed above.
Models were compared by use of penalized expected de-
viance20 alongside a forward selection approach. Penalized
expected deviance is a loss function that penalizes for model
complexity and is suitable for complex hierarchical models.
These models were then used to assess the probability that
new patients would not achieve remission within 5 years of
starting treatment in a discriminant analysis. The best com-
bination of longitudinal variables was determined by proba-
bility of correct classiﬁcation. Training sets consisting of data
from 70% of patients in each group were used to build the
model, and data from the remaining 30% were used to test the
model. Training and test sets were randomly generated 100
times, and the results were averaged.
Dynamic classification scheme
To classify patients as remission or no remission, we used the
following procedure. First, the risk of not achieving remission
for each patient was predicted with the multivariable model.
Second, we stated a threshold for the predictive risk. The
threshold chosen in this work is 0.64, which was associated
with the point on the receiver operator characteristic curve
nearest to the top left corner (i.e., it provides the best balance
in terms of number of patients correctly identiﬁed as no re-
mission and those correctly identiﬁed as 12-month seizure-
free patients). Third, the uncertainty of the risks predicted by
the model varies across patients (and over time). To account
for this uncertainty, credible intervals (bayesian equivalent of
conﬁdence intervals [CIs], an interval in which we are 99%
conﬁdent that the true probability of not achieving remission
during 5 years lies) were used to assess the conﬁdence in the
assigned risk.21
We applied the following allocation scheme:
1. We consider the ﬁrst visit of a patient and calculate both
the probability of the patient not to achieve remission
during 5 years after starting treatment and a 99% credible
interval around this probability.
2. If the credible interval is entirely above the threshold of
0.64, we assign the patient to the no-remission group.
Prediction now stops for this patient because the patient
shows a high risk of not achieving remission.
3. If the credible interval is entirely below 0.64, we
temporarily assign the patient to the remission group
and update the patient’s risk at the next visit.
4. If the credible interval contains 0.64, the patient remains
unclassiﬁed (because of the level of uncertainty in the
estimated risk, the patient is not yet assigned to a group).
Their risk is updated at the next visit.
Data availability
Anonymized data used in this study are available on request
from Dr. Marson.
Results
Figure 1 shows the disposition of patients recruited to
SANAD who were included in the analyses reported here.
Table 1 shows their baseline variables.
The best multivariate models consisted of 2 longitudinal
variables: whether the patient experienced seizures since the
last clinic visit and whether the patient’s treatment was
changed at the last clinic visit. The baseline covariates in-
cluded in each model, along with their odds ratios, are de-
scribed in table 2.
Having focal epilepsy increases the risk of experiencing seiz-
ures, regardless of whether the patient will ultimately experi-
ence remission (table 2). Having a ﬁrst-degree relative with
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epilepsy or neurologic insult increases the risk for patients
who will ultimately achieve remission. These variables were
not selected in the model for patients who do not achieve
remission, although this could be due to smaller sample size.
Figure 2 describes how the assigned probability of not
achieving remission changes according to follow-up factors.
Patients who experienced seizures or whose treatment was
changed since the previous visit tend to be assigned higher
probabilities of not achieving remission. These assigned
probabilities increase as the length of observation increases for
a patient. In general, patients with a history of neurologic
insult are assigned lower probabilities of ultimately being no
remission compared to patients with similar seizure and
treatment history but without neurologic insult, especially
early in their observation history (e.g., 1 year), reﬂecting the
fact that patients with neurologic insult are more likely to
experience seizures,13 at least initially, regardless of whether
they will ultimately achieve remission.
Figure 3 illustrates the allocation scheme for 4 real scenarios.
Patient A initially has a low probability of not achieving re-
mission because, despite having experienced seizures, the time
of observation is still short. At the next visit, the risk drops
because a treatment change led to a short period free from
seizures. As more information is gathered on the patient, the
patient’s probability of not achieving remission increases, but
only after the ﬁfth visit is the entire 99% credible interval
above the chosen threshold of 0.64. At this point, we are more
conﬁdent this patient is not going to achieve remission be-
cause the patient has changed treatment 3 times and is still
experiencing seizures. This patient is classiﬁed as no remission
within 2 years, a much earlier time point than the decision
might otherwise be made in clinical practice.
Patient B takes longer to be classiﬁed as no remission. After 2
years, the patient changed treatment, and it resulted in a pe-
riod without seizures, which caused the assigned probability of
not achieving remission to decrease dramatically, oﬀering
hope that this patient may achieve remission. Unfortunately
for this patient, the seizures returned, causing a steady in-
crease in the probability of being in the no-remission group,
Table 1 Baseline characteristics of patients included in SANAD, MESS, and NGPSE
Patient group
Dataset
SANAD MESS15,23 NGPSE16
Remission
within 5 y
No
remission
within 5 y
Remission
within 5 y
No
remission
within 5 y
Remission
within 5 y
No
remission
within 5 y
Patients, n (%) 1,577 (90) 175 (10) 753 (98) 12 (2) 586 (93) 45 (7)
Male, n (%) 911 (58) 95 (54) 411 (54) 9 (75) 298 (51) 19 (42)
Median age at start of
treatment, y
32 31 22 34 26 22
Focal epilepsy, n (%) 957 (61) 136 (78) 306 (41) 6 (50) 247 (42) 29 (64)
Generalized epilepsy, n (%) 376 (24) 24 (14) 432 (57) 6 (50) 157 (27) 10 (22)
Neurologic insult, n (%) 155 (10) 35 (20) 45 (6) 2 (17) 234 (40) 21 (47)
First-degree relativewith epilepsy, n (%) 298 (13) 25 (14) 91 (12) 2 (17) 68 (12) 4 (9)
Total seizures before start of
treatment, median, n
8 50 2 1.5 1 1
Abbreviations: MESS = Multicentre Study of Early Epilepsy and Single Seizures; NGPSE = National General Practice Study of Epilepsy; SANAD = Standard and
New Antiepileptic Drug.
Figure 1 Standard and New Antiepileptic Drugs trial profile
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until the patient is conﬁdently predicted to be no remission
after just over 4 years.
Patient C achieves remission immediately after 12 months.
This is accurately predicted by the model because the patient
experiences no seizures after the start of treatment and the
clinicians felt no need to change treatments. In contrast, pa-
tient D experienced seizures for a longer period. That patient
had focal epilepsy, had a high number of seizures before
starting treatment, and was relatively young, which meant that
although the patient continued experiencing seizures for >2
years, the risk of not achieving remission was not initially high
because seizures were likely to occur according to these
baseline characteristics. Just over 3 years after starting treat-
ment, the patient is observed to have changed to a treatment
that appears to give adequate seizure control and is correctly
classiﬁed as remission.
The overall accuracy of our predictive model is assessed by
considering how many patients from the test sample were
correctly classiﬁed. With the use of the selected threshold of
0.64 and the exclusion of patients left unclassiﬁed by the
model, 95% of patients who truly did not achieve remission
were identiﬁed as such (sensitivity, 95% CI 89.6%–100%),
while 97% of patients who achieved remission were correctly
classiﬁed (speciﬁcity, 95% CI 93.3%–98.8%). Overall, 97%
(95% CI 93.4%–98.5%) of patients were correctly classiﬁed.
For patients predicted by the model as not achieving re-
mission, 76% (95% CI 58.5%–88.2%) truly did not achieve
remission (positive predictive value [PPV]). The area under
the receiver operator characteristic curve (AUC) was 94.5%
(95% CI 90.9.0%–96.7%).
A randomly chosen split of the data into training and test sets
achieved a calibration slope of 0.922, suggesting that the model
is well calibrated (calibration slopes close to 1 show well-
calibrated models with observed and expected risks matching
well), in addition to providing good discrimination between
patients who achieve remission and those who do not.22
Five percent of patients were left unclassiﬁed, and including
these patients, the model achieved an overall sensitivity of
Table 2 Covariates selected in the multivariate models
Group Variable
Longitudinal variable
Seizures since last visit Treatment changed at last visit
Odds ratio 95% CI Odds ratio 95% CI
Patients who achieve remission No. of seizures before start of
treatment (per 10 seizures)
1.010 1.007–1.014 1.005 1.003–1.007
Neurologic insult present 1.576 1.097–2.288
Focal epilepsy (vs generalized) 1.755 1.281–2.461
Unclassified epilepsy (vs generalized) 0.903 0.582–1.394
Age at start of treatment (per 10 y) 0.861 0.802–0.924
First-degree relative with epilepsy 1.804 1.218–2.693 1.178 0.957–1.462
Male 0.996 0.878–1.139
Time since last follow-up (mo) 0.989 0.963–1.017 0.963 0.945–0.981
Time since start of treatment (mo) 0.900 0.889–0.911 1.003 0.995–1.010
Patients who do not
achieve remission
No. of seizures before start of treatment
(per 10 seizures)
1.005 0.999–1.011
Focal epilepsy (vs generalized) 1.900 0.982–3.637
Unclassified epilepsy (vs generalized) 0.624 0.271–1.460
Time since last follow-up (mo) 1.399 1.263–1.544 0.967 0.942–0.994
Time since start of treatment (mo) 1.018 1.004–1.032 1.014 1.007–1.022
Abbreviation: CI = confidence interval.
Odds ratios and their 95% CIs are shown for the covariates of the models of both remission and no-remission patients. Blank entries show that the variable
was not selected. The model included a patient-specific random intercept for each longitudinal variable. For patients who achieve remission, the risk of
experiencing seizures increases by >50% in patients with a history of neurologic insult (odds ratio 1.58), increases by ≈75% in patients with focal epilepsy (odds
ratio 1.76) and in patients with a first-degree relative with epilepsy (odds ratio 1.80), and decreases by ≈14% by every 10 years of age (odds ratio 0.86). The risk
of experiencing seizures decreases by 10% per month since starting treatment (odds ratio 0.90). The number of seizures before the start of treatment,
although statistically significant, was not clinically relevant (1% increase in risk per 10 seizures). For patients who do not achieve remission, the risk of
experiencing seizures almost doubles in patientswith focal epilepsy (odds ratio 1.9, although the result is not statistically significant) and increases by ≈2%/mo
since the start of treatment (odds ratio 1.02).
Neurology.org/N Neurology | Volume 91, Number 22 | November 27, 2018 e2039
78% and speciﬁcity of 93% with a probability of correct
classiﬁcation of 91%.
The average time at which a patient was correctly identiﬁed as
not achieving remission was 36.4 months (just over 3 years).
In fact, 51% of patients who were correctly identiﬁed as not
achieving remission were identiﬁed within 3 years, while only
10% required a visit in their ﬁfth year after starting treatment
to be correctly classiﬁed (table 3). For most patients who will
not achieve remission, our model can identify them between 1
and 3 years. Our model is patient speciﬁc. The classiﬁcation of
no remission is not made at the same time for all patients
(unlike the previously published predictive models8–10) but
only when their individual risk is high enough.
With the use of the dynamic classiﬁcation scheme with 99%
credible intervals, only 5% of patients were left unclassiﬁed
and would require further follow-up in clinical practice to
determine their classiﬁcation. The time of prediction is less
important for patients who achieve remission because these
patients would in practice remain under observations until
remission is observed. Nevertheless, 973 of 1,577 patients
(62%) who achieve remission can be correctly identiﬁed with
only observations from their ﬁrst year of follow-up.
External validation
We conducted an external validation study of our predictive
model using 2 additional datasets: MESS15,23 and NGPSE
(table 1 for descriptive details).16 MESS was a United
Kingdom–based randomized controlled trial comparing
immediate and deferred treatment for patients who expe-
rienced a ﬁrst unprovoked seizure or had epilepsy. NGPSE
is an unselected cohort from the UK primary care system of
people with newly diagnosed seizures. We used the model
built using all the SANAD data to predict the status of
patients in MESS and NGPSE and assessed the accuracy of
the predictions. In the NGPSE data, all counts of ≥11
seizures were recorded as >10. This aﬀected only a rela-
tively small number of patients (9 of 45 no-remission
patients and 57 of 586 remission patients). Following
previous examples,24 we used various missing data impu-
tation methods to assign values >10 for the total number of
seizures before starting treatment to the relevant patients in
NGPSE. The diﬀerent imputation methods used gave al-
most identical results, so only the hot deck imputation is
reported here.
The accuracy in terms of sensitivity and speciﬁcity of the
classiﬁed patients when the predictive model is applied to
Figure 2 Probability of no remission within 5 years of starting treatment for combinations of risk factors at 3 chosen time
points
Box represents the point estimate average of the predicted probability of not being in remission for patients with the given characteristics; line represents the
99% credible interval. Seizures and treatment change columns refer to the period since the last clinic visit, while neurologic insult and total seizures are
recorded at baseline. The risks are calculated at 1, 2, and 3 years after starting treatment.
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MESS and NGPSE is high (table 4, i.e., sensitivity >90% and
speciﬁcity >95% for classiﬁed patients, only 1% of patients left
unclassiﬁed) and comparable to the prediction accuracy
within SANAD (obtained by splitting the data into training
and test sets). In both the MESS and NGPSE cohorts, very
high AUC values demonstrate excellent model discrimina-
tion. For the MESS data set, the PPV was lower, although we
suspect this is due to the low proportion of patients who do
not achieve remission.
The NGPSE cohort was well calibrated, achieving a calibra-
tion slope of 0.95, suggesting that the SANAD model is well
calibrated and discriminates well even in this external dataset.
The MESS cohort achieved, on the other hand, a calibration
slope of 0.52. Calibration slopes in external datasets are often
worse than in the dataset used to train the model. In the case
of the MESS cohort, the worse calibration slope is likely also
to be inﬂuenced by the low proportion of patients who do not
achieve remission, as was seen in the PPV value for MESS.
Figure 3 Profiles of risk for 2 no-remission patients correctly classified 2 years (patient A) and just over 4 years (patient B)
after starting treatment and for 2 patients with remission correctly classified soon (patient C) and ≈3 years
(patient D) after starting treatment
Points represent the probability assigned to the patient, while the bars show the 99% credible interval around each probability of no remission. The observations
recorded along the top of each plot indicatewhether thepatient experienced seizures (SZ) since the last visit andwhether treatmentwas changed at last visit (TC);
the information on the left of each plot describes some baseline characteristics for each patients. Light yellow bars show the selected threshold of 0.64. Gray box
shows the remaining period of the 5 years since starting treatment once a patient’s status has been predicted. F = focal; U = unclassified.
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This external validation shows that the SANAD model was
able to correctly identify people with epilepsy who would not
achieve remission from seizures within 5 years of beginning
treatment with a high degree of accuracy.
Diﬀerences are nevertheless expected because the datasets are
not identical in purpose or form but can be considered to
come from the same “superpopulation” as required for ex-
ternal validation.22
Discussion
Our dynamic prediction approach allows the identiﬁcation of
patients whowill not achieve remission within 5 years of starting
treatment. The time at which nonremission is identiﬁed is dif-
ferent among patients, reﬂecting the heterogeneous nature of
epilepsy and patient trajectories. For classiﬁed patients, 95%
of no-remission cases are correctly identiﬁed, and the majority
of these patients are identiﬁed within the ﬁrst 3 years after
beginning treatment. Some patients are clearly missed by
remaining unclassiﬁed, and the overall sensitivity would be re-
duced to 78% by taking into account unclassiﬁed patients.
The most informative evidence in terms of predicting
a patient’s epilepsy status is the combination of treatment
changes and seizure history together with baseline factors that
accurately predicts a patient’s prognosis. Note that these
results do not imply that changing treatment causes an in-
creased likelihood of not achieving remission because
changing treatment has been shown to usually be beneﬁcial.25
Instead, the fact that a clinician felt the need to change the
dose or type of the AED at the previous visit is used as an
indicator that something was not going well.
While clinicians may at ﬁrst be concerned about choice of
drug and dosing and the eﬀect that choice might have on
prognosis, it is important to consider that randomized con-
trolled trials in epilepsy have largely failed to ﬁnd important
diﬀerences among AEDs. This was exempliﬁed by the use of
noninferiority designs in the European Union and historical
controlled withdrawal to monotherapy trials in the United
States. In contrast, we have clearly demonstrated the eﬀect of
clinical factors on outcome.
The International League Against Epilepsy proposed a deﬁ-
nition of drug-resistant epilepsy as the failure of adequate
trials of 2 tolerated and appropriately chosen and used AED
schedules (whether as monotherapies or in combination) to
achieve sustained seizure freedom.2 This deﬁnition, however,
is of little use in clinical practice (e.g., “adequate” and “ap-
propriately chosen” are subject to interpretation, and the
Table 3 Summary of the classification accuracy of the model showing the number of patients correctly identified as no
remission or remission by yearly intervals
Correctly classified as no remission, n (%) 138 (79) 138 (95) Correctly classified as remission, n (%) 1,467 (93) 1,467 (97)
Patients who do not achieve remission (n = 175) Patients who achieve remission (n = 1,577)
<1 y 0 (0) <1 y 973 (66)
1–2 y 9 (7) 1–2 y 395 (27)
2–3 y 61 (44) 2–3 y 72 (5)
3–4 y 54 (39) 3–4 y 26 (2)
>4 y 14 (10) >4 y 1 (<1)
Misclassified as remission, n (%) 7 (4) 7 (5) Misclassified as no remission, n (%) 47 (3) 47 (3)
Unclassified, n (%) 30 (17) Unclassified, n (%) 63 (4)
The percentages were calculated as averages across 100 test sets but are reported also as numbers out of the whole data set to give an overall impression.
Table 4 Summary of the predictive accuracy for SANAD, MESS, and NGPSE
Data and modifications Sensitivity Specificity PCC PPV AUC Unclassified, % Mean prediction time, mo
SANAD 0.95 0.97 0.97 0.76 0.94 5 36.4
MESS 0.91 0.98 0.98 0.36 0.98 1 37.9
NGPSE (hot deck) 0.93 0.97 0.96 0.67 0.98 1 35.6
Abbreviations: AUC = area under the curve; MESS = Multicentre Study of Early Epilepsy and Single Seizures; NGPSE = National General Practice Study of
Epilepsy; PCC = probability of correct classification; PPV = positive predictive value; SANAD = Standard and New Antiepileptic Drug.
The SANAD results report the averages over 100 splits of the data into 70% training sets and 30% test sets.
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choice of 2 AEDs is arbitrary), and patients currently wait
years before clinicians are conﬁdent that they will not achieve
remission. In contrast, our analysis includes dose and drug
changes, thereby using information about treatment in a more
quantiﬁable and informative way, avoiding any need to make
judgments about adequacy and appropriateness.
In our dataset, a total of 600 (of 1752) patients (34%) stopped
taking their randomized drug. However, 413 of these 600
patients were changed to a diﬀerent drug, and 187 received no
AEDs (of whom 159 [85%] achieved remission).
Patients who did not achieve remission from seizures within 5
years of starting treatment had an average of 5.2 treatments
changes (either a change in dose or the addition or removal of
an AED) over the duration of the 5 years for which they were
observed. Patients who were correctly identiﬁed as not
achieving remission by our model had undergone an average
of 3.9 treatment changes at the point at which they were
correctly identiﬁed. The International League Against Epi-
lepsy deﬁnition of drug-resistance requires only 2 changes in
treatment to classify a patient as drug resistant. Our analysis
suggests that, in practice, more treatment changes occur be-
fore we can be conﬁdent a patient will not achieve remission.
Previous models have deﬁned remission/no remission diﬀer-
ently from us, so a direct comparison is not possible. However,
in the prediction of terminal remission at 5 years after diagnosis
using baseline characteristics,8 a sensitivity of 65%, a speciﬁcity
of 64%, a PPV of 36%, anNPV of 85%, and an AUCof 0.7 were
achieved. When the prediction used data collected during
a 6-month follow-up period,8 these values increased slightly to
69%, 71%, 43%, 88%, and 77%, respectively. A model that was
built to predict drug resistance after 10 years (based on values at
1 year of follow-up) reported AUCs between 61% and 76%.10
Finally, a model developed to predict 2-year status after 6
months of follow-up reports an AUC of 77.97%.9 The pre-
dictive accuracies from our model reported above are higher
than these values (even when sensitivity/speciﬁcity accounts
for the unclassiﬁed patients).
The optimal threshold should be selected according to the
clinical objective. A higher threshold will produce greater
speciﬁcity and greater PPV, but a longer time is required on
average to identify patients who will not achieve remission.
Conversely, a lower threshold will reduce the time required to
identify patients who will not achieve remission; the sensi-
tivity of the test will increase but at the cost of a reduction in
speciﬁcity.
The baseline characteristics inﬂuence the time at which
a patient’s status can be conﬁdently predicted, while seizure
and treatment history have the largest inﬂuence on the pre-
dicted status. This discovery is illustrated by comparing the
ﬁrst visits of patients A and B in ﬁgure 3. Patient B has
characteristics at the start of treatment that are associated with
an increased likelihood of experiencing seizures for at least
some time, whereas patient A has characteristics that would
not lead a clinician to expect that the patient would experience
seizures. Their ﬁrst visits occur at approximately the same
time, and they both have experienced seizures and are still on
the ﬁrst treatment assigned. However, at baseline, patient A is
assigned a probability of not achieving remission that is 5%
higher compared to that of patient B because it is expected
that patient B experienced seizures. Because patient A con-
tinues to experience seizures, the estimated risk that the pa-
tient will ultimately not achieve remission increases much
more quickly than for patient B.
A limitation of the model is that patients who achieve re-
mission are considered only up to the point at which they ﬁrst
achieve remission. In the SANAD data, 532 of 1,577 patients
who were observed to achieve a 12-month remission went on
to have further seizures (34%) while under observation. Of
these, 183 (34%) experienced 1 further seizure only, and 236
of 532 patients (44%) were observed to achieve 12-month
remission again.
A number of patients with insuﬃcient follow-up time to de-
termine their 5-year status were excluded from the analysis
(n = 545, mostly administrative censoring). In addition, 34
patients dropped out of the study before it was possible to
determine their status; therefore, it was not possible for these
patients to be included in the analysis. The omission of this
group of patients may have an inﬂuence on the model
parameters for each multivariate generalized linear mixed
model and hence also on the discriminant analysis. However,
given that this exclusion is dictated mainly by the time of
starting treatment, we do not expect that this led to biased
results.
Although a group of patients have been excluded from this
analysis, the proportion of patients achieving a 12-month
remission within 5 years of follow-up is comparable to that in
previous studies, suggesting that the included cohort is rea-
sonably representative of people with epilepsy. Previous
estimates suggest that 60% to 70% of people will achieve
remission from seizure, deﬁned as a 5-year period of contin-
uous remission within 9 years of follow-up.26 Table 1 in that
study reports that after 5 years of follow-up, 93% (91%–95%)
of patients had achieved a 12-month remission interval, which
is comparable to the 90% observed in this study.
Although possible, we do not expect that the imputation of
the number of seizures in the NGPSE dataset has dramatically
increased the degree of agreement with SANAD given that
this was applied to only a relatively small number of
patients (10%).
This is a step toward a clinical tool for identifying patients who
will not achieve remission from seizures. The model has been
internally and externally validated, and it has the potential to
be used in clinical practice to aid the stratiﬁcation of patient
management and to inﬂuence patient counseling.
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Patients who will not achieve remission can be identiﬁed by
recording at baseline (at the beginning of treatment with
AEDs) the following information: patient’s age, sex, type of
epilepsy, number of seizures experienced before treatment,
whether the patient had a ﬁrst-degree relative with epilepsy,
and whether the patient had a neurologic insult, as well as by
monitoring over time whether the patient had experienced
seizures since the last clinic visit and whether the clinician had
felt it necessary to change treatment at the last visit. Because
a small group of patients are unclassiﬁed, increased conﬁdence
is obtained in the predictions of those patients who are clas-
siﬁed as not likely to achieve remission. This selection of
baseline and longitudinal variables, along with the times of the
clinic visits after baseline, is suﬃcient to classify patients with
high levels of accuracy.
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